Navigation Links
Cephalon Reports Record Earnings and Raises 2010 Guidance
Date:10/28/2010

FRAZER, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2010 sales of $707.1 million, a 32 percent increase compared to sales of $535.2 million for the third quarter 2009.  Basic income per common share for the quarter was $1.76.  Excluding amortization expense and certain other items, basic adjusted income per common share for the quarter was $2.27, a 34 percent increase over the $1.70 for the third quarter of 2009.   Adjusted net income for the third quarter of 2010 was $170.7 million, a 35 percent increase over the $126.7 million for the third quarter of 2009.

Central nervous system (CNS) franchise sales were $354.3 million during the quarter, a 19 percent increase compared to the same period last year.  Pain franchise sales were $131.2 million, a 10 percent increase versus third quarter 2009.  Oncology franchise sales were $132.9 million, a 60 percent increase over the same period last year due to strong sales of TREANDA® (bendamustine HCL) for Injection.  Other product sales were $88.8 million, an increase of 153 percent versus third quarter of 2009 primarily due to the acquisition of Mepha in the second quarter of 2010.  

"We achieved record earnings and cash flow from operations in the quarter while continuing to expand our global product offerings," said Kevin Buchi, Chief Operating Officer. "Our robust cash flow generation gives us the flexibility to invest in our rich pipeline while continuing our active business development efforts, positioning us very well for the future."

The company is updating its guidance for full year 2010.  Total sales guidance is $2.69-$2.73 billion. This includes expected CNS franchise sales of $1.34-$1.37 billion, pain franchise sales of $510-$530 million, oncology franchise sales of $500-$520 million, and other product sales of
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
2. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
3. Cephalon Completes Acquisition of Arana Therapeutics
4. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
7. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
8. Cephalons New Product Launches Pace Record 2008 Sales
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
11. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... Inclinix, Inc. a contract,research organization that hires ... new drugs, today announced restructuring of positions to,support ... of,40% in 2007 and the infusion of $10 ... Frontier Capital, a private equity firm., Diane ...
... SAN FRANCISCO, June 3 VIA Pharmaceuticals,(Nasdaq: ... development of,compounds for the treatment of cardiovascular disease, ... chief executive officer of VIA, and,James G. Stewart, ... a company update at the Seventh Annual Needham ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical Technology, Inc (OTC ... of plant extracts and pharmaceutical raw materials,for ... released an,update on its business following their ... "In the first quarter, sales of our ...
Cached Biology Technology:Inclinix Expansion Creates New Position and Promotions 2Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification 2
(Date:7/11/2014)... that cannabinoid receptor type 1 can inhibit ... and reduce neurotransmitter release. However, some scholars ... increase extracellular Ca2+ influx and increase neurotransmitter ... Tongji Hospital Affiliated to Tongji Medical College, ... used whole cell voltage-clamp and calcium imaging ...
(Date:7/10/2014)... Colo. , June 27, 2014  The ... the National Institute of Standards and Technology (NIST) ... of its academic research and forensic science expert ... The Board is an element of the NIST,s ... members are among the first appointments made to ...
(Date:7/10/2014)... N.Y. , July 2, 2014 It ... (ABD) to announce the appointment of the world-renowned Thoracic ... Board of Directors. Dr. Ginsburg, with over ... facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical ... Pacemaker since the late 1980,s and is considered an ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... to developing new antibiotics, and a technique called solid-state ... , That's the view of University of Michigan ... toward that goal March 3 at the annual meeting ... Ramamoorthy's research group is using solid-state NMR to explore ...
... Flavonoids, a group of compounds found in fruits and ... for their antioxidant activity, actually have little or no ... scientists in the Linus Pauling Institute at Oregon State ... human health, but for reasons that are quite different ...
... of the persistent riddles of the deadly 1918 Spanish ... varying severity. Why were some municipalities such as St. ... Philadelphia when both implemented similar public health measures? What ... by the National Institutes of Health (NIH), was not ...
Cached Biology News:Natural antibiotics yield secrets to atom-level imaging technique 2Natural antibiotics yield secrets to atom-level imaging technique 3Studies force new view on biology of flavonoids 2Studies force new view on biology of flavonoids 3Rapid response was crucial to containing the 1918 flu pandemic 2Rapid response was crucial to containing the 1918 flu pandemic 3Rapid response was crucial to containing the 1918 flu pandemic 4
... workstation is the simplest, easiest-to-use system ever ... liquid handling capabilities,into their labs, or groups ... routine applications on a separate instrument. Plate-handling ... even when you have thousands of ...
... has generated hybridomas against a large ... initiation, you are provided with personalized ... cell lines developed by Covance remain ... typical hybridoma development project has four ...
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
... ENGENISTM (Entire Gene/cDNA or Isolated Sequence) siRNA ... quantitative approach for evaluation of a potential ... an efficient target for RNA interference (RNAi). ... not perfect, leaving the probability of selected ...
Biology Products: